FryarCD, CarrollMD, AffulJ. Prevalence of overweight, obesity, and severe obesity among adults aged 20 and over: United States, 1960–1962 through 2017–2018. NCHS Health E-Stats2020.
2.
AhmadFB, CisewskiJA, MiniñoA, . Provisional Mortality Data - United States, 2020. MMWR Morb Mortal Wkly Rep2021;70:519–22. [Erratum in: MMWR Morb Mortal Wkly Rep. 2021 Jun 18;70(24):900].doi:10.15585/mmwr.mm7014e1http://www.ncbi.nlm.nih.gov/pubmed/33830988
3.
TartofSY, QianL, HongV, . Obesity and mortality among patients diagnosed with COVID-19: results from an integrated health care organization. Ann Intern Med2020;173:773–81.doi:10.7326/M20-3742http://www.ncbi.nlm.nih.gov/pubmed/32783686
4.
GeL, SadeghiradB, BallGDC, . Comparison of dietary macronutrient patterns of 14 popular named dietary programmes for weight and cardiovascular risk factor reduction in adults: systematic review and network meta-analysis of randomised trials. BMJ2020;369:m696. [Erratum in: BMJ. 2020 Aug 5;370:m3095]. doi:10.1136/bmj.m696http://www.ncbi.nlm.nih.gov/pubmed/32238384
5.
SaxonDR, IwamotoSJ, MettenbrinkCJ, . Antiobesity medication use in 2.2 million adults across eight large health care organizations: 2009-2015. Obesity2019;27:1975–81.doi:10.1002/oby.22581http://www.ncbi.nlm.nih.gov/pubmed/31603630
6.
GarberAJ, HandelsmanY, GrunbergerG, . Consensus statement by the American association of clinical endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management algorithm - 2020 executive summary. Endocr Pract2020;26:107–39.doi:10.4158/CS-2019-0472http://www.ncbi.nlm.nih.gov/pubmed/32022600
7.
GarveyWT, BirkenfeldAL, DickerD, . Efficacy and safety of liraglutide 3.0 Mg in individuals with overweight or obesity and type 2 diabetes treated with basal insulin: the scale insulin randomized controlled trial. Diabetes Care2020;43:1085–93.doi:10.2337/dc19-1745http://www.ncbi.nlm.nih.gov/pubmed/32139381
8.
WildingJPH, BatterhamRL, CalannaS, . Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med2021;384:989–1002.doi:10.1056/NEJMoa2032183http://www.ncbi.nlm.nih.gov/pubmed/33567185
9.
WaddenTA, BaileyTS, BillingsLK, . Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the step 3 randomized clinical trial. JAMA2021;325:1403–13.doi:10.1001/jama.2021.1831http://www.ncbi.nlm.nih.gov/pubmed/33625476
10.
WolfeBM, KvachE, EckelRH. Treatment of obesity: weight loss and bariatric surgery. Circ Res2016;118:1844–55.doi:10.1161/CIRCRESAHA.116.307591http://www.ncbi.nlm.nih.gov/pubmed/27230645
